Skip to main content

ARDS

Stock

Performance overview

ARDS Price
Price Chart

Forward-looking statistics

Beta
0.57
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

Sector
Industry
Website
Employees
Market cap

Fundamentals

Enterprise value$4.8M
Revenue$22.4M
Revenue per employee
Profit margin-5.11%
Debt to equity-0.41

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.16
Dividend per share
Revenue per share$0.70
Avg trading volume (30 day)$1
Avg trading volume (10 day)$1
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-0.00
Price to sales0.00
P/E Ratio-0.00
Enterprise Value to Revenue0.21
Price to book-0.00

Upcoming events

Next earnings dayNovember 21, 2022
Next dividend day
Ex. dividend day

News

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

Zacks Investment Research (July 13, 2023)
Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant.  Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration.

Benzinga (February 17, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free